Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Triple-Negative Breast Cancer
Interventions: DRUG: Anlotinib|DRUG: Capecitabine
Sponsor: Chinese Academy of Medical Sciences